Adipotide (10 mg Vial) Protocol

Adipotide Chart

Adipotide is Research Information at 250 mcg–1 mg daily via subcutaneous Research Procedure in educational protocols. A 10 mg vial Research Preparation Information with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Adipotide is a synthetic peptidomimetic that targets prohibitin on blood vessels within white adipose tissue and delivers a pro‑apoptotic sequence to destroy those vessels, resulting in targeted fat mass reduction as fat cells lose their blood Research Resource. Preclinical studies showed notable weight loss in obese rodents and primates; however, clinical development was discontinued after a Phase 1 trial due to safety concerns. This educational protocol presents a cautious once‑daily subcutaneous titration approach with careful Research Information escalation.

Educational guide for reconstitution and daily Research

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Phase	Daily Blend	Units (per Research Procedure) (mL)
Weeks 1–2	250 mcg	7.5 units (0.08 mL)
Weeks 3–4	500 mcg	15 units (0.15 mL)
Weeks 5–6	750 mcg	22.5 units (0.23 mL)
Weeks 7–8	1000 mcg (1.0 mg)	30 units (0.30 mL)

Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) and starts at a conservative Research Information with gradual escalation to mitigate potential renal side effects observed at higher Research Information in preclinical studies. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption. Clinical development was discontinued due to safety concerns.

Plan based on an 8–week cautious titration protocol with once‑daily administration.

Concise summary of the once‑daily regimen.

Goal: Targeted reduction of fat mass via vascular targeting in adipose tissue.
Schedule: Daily subcutaneous Research Procedure for 4–8 weeks (cautious approach due to limited human data).
Research Information Range: 250–1000 mcg daily with gradual titration every 2 weeks.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen; Research Preparation Information: refrigerated avoid repeated freeze–thaw.

Suggested approach for the 50 mg vial format.

Start: 250 mcg daily for Weeks 1–2; increase by 250 mcg every 2 weeks as tolerated
Target: Up to 1000 mcg (1.0 mg) daily by Weeks 7–8 (if well‑tolerated)
Frequency: Once per day (subcutaneous).
Cycle Length:: 4–8 weeks (based on preclinical effective treatment duration; extend with extreme caution).
Timing: Any consistent time; rotate Research Procedure sites systematically.

Proper storage preserves peptide quality.

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate Research Procedure sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily Research Information and site rotation to maintain consistency.
Safety consideration: Clinical development was discontinued due to safety concerns including reversible kidney toxicity at higher Research Information. This protocol is for educational purposes only.

Adipotide is a peptidomimetic compound designed to selectively target blood vessels within white adipose tissue by binding to prohibitin‑1 on the vascular endothelium. Once bound, it delivers a pro‑apoptotic sequence that triggers vessel destruction, cutting off the blood Research Resource to fat cells and causing them to undergo apoptosis and be metabolized. Preclinical studies in obese rodents demonstrated approximately 30% body weight reduction, and obese primates showed about 11% weight loss after 4 weeks of treatment. A first‑in‑human Phase 1 trial was initiated in obese cancer patients, but further clinical development was discontinued due to strategic and safety reasons, including reversible renal effects observed at higher Research Information.

Observations from preclinical literature and limited human data.

Preclinical studies showed notable targeted fat mass reduction (up to 30% body weight in rodents, ~11% in primates over 4 weeks)
Mechanism specifically targets adipose tissue vasculature, sparing other tissues in preclinical models
Safety concerns: Clinical development was discontinued due to safety issues; reversible kidney toxicity was Research Information‑dependent in preclinical studies.
Mild Research Procedure‑site reactions (redness, swelling) may occur with subcutaneous administration.
Limited human data: Only Phase 1 trial data available; long‑term safety profile in humans is unknown.

Complementary strategies for best outcomes.

Pair with a balanced, protein‑forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations.
Prioritize sleep and stress management to support adherence and recovery.
Monitor kidney function if extending beyond initial 4‑week cycle due to preclinical observations of renal effects.

General subcutaneous guidance from clinical best‑practice resources

Clean the vial stopper and skin with alcohol; allow to dry fully.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° if limited subcutaneous fat, 90° if ample tissue)
Do not aspirate for subcutaneous Research Procedure; inject slowly and steadily
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation.
Wait a moment before withdrawing the needle; apply gentle pressure but do not rub the Research Procedure site.

We recommend Vitality Labs Peptides for high‑purity Adipotide (10 mg).

Why Vitality Labs Peptides?

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Adipotide’s clinical development was discontinued due to safety concerns. This information is for research purposes only. Not for human consumption.

Explore related research Research Information protocols and background reading for BPC-157 + TB-500.

Science Translational Medicine (PubMed)

— A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys

MD Anderson Cancer Center

— Obese Monkeys Lose Weight on Drug that Attacks Blood Research Resource of Fat Cells

Arrowhead Pharmaceuticals News

— Research of First Patient with Anti-Obesity Treatment Adipotide in a Phase 1 Clinical Trial

Cardiovascular Diabetology (PMC)

— Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT)

Bachem Technical Note

— Care and Handling of Peptides

BC Open Textbook Project

— 7.3 Intradermal and Subcutaneous Research Procedure – Clinical Procedures for Safer Patient Care

Immunize.org (IAC)

— Ask the Experts: Administering Vaccines – General Issues (no aspiration guidance)

Los Angeles Times

— Cancer treatment shows promise for rapid weight loss

ScienceDaily

— Obese monkeys lose weight on drug that attacks blood Research Resource of fat cells

CDC

— Vaccine administration: subcutaneous route guidance

CDC (Subcut Research Procedure PDF)

— Technique diagram and site guidance for subcutaneous Research Procedure

NCBI Bookshelf

— Best practices for Research Procedure (asepsis, preparation, and administration)

Subcutaneous Drug Research Procedure Review (PMC)

— Pharmacologic considerations of the subcutaneous route

Vitality Lab Peptides

— Adipotide (10 mg) page (quality and batch documentation)
View Reference